Conmana Combined With Thalidomide to Treat NSCLC

Summary

Our study the NSCLC harbors EGFR-mutation with Conmana combined with thalidomide as first-line treatment, is expected to improve further EGFR-Tyrosine kinase inhibitors (TKI) response rate (ORR), prolong time to progression (PFS), improve patient survival.

Timeline

Start

2016-03

Primary completion

2017-03

Completion

2020-03

Drugs

Indications